OncoMatch/Clinical Trials/NCT06634589
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Is NCT06634589 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for b-cell malignancy.
Treatment: Tacabrutideg · Sonrotoclax · Zanubrutinib · Mosunetuzumab · Glofitamab · Obinutuzumab — The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: none (treatment-naive B-cell malignancies)
Treatment-naive B-cell malignancies
Cannot have received: Bcl-2 inhibitor
Exception: participants who relapsed ≥ 24 months after completion of a full course of a prior Bcl-2 inhibitor containing regimen
Prior treatment with a B-cell lymphoma-2 (Bcl-2) inhibitor (with exception for participants who relapsed ≥ 24 months after completion of a full course of a prior Bcl-2 inhibitor containing regimen)
Cannot have received: CD20 x CD3 T-cell engager antibody
Prior exposure to a CD20 x CD3 T-cell engager antibody treatment
Cannot have received: allogeneic stem cell transplant with active graft-versus-host disease
Exception: Substudies 1 and 2: with active GVHD, or requiring immunosuppressive drugs for treatment of GVHD, or who have taken calcineurin inhibitors within 4 weeks prior to consent; Substudies 3 and 4: all participants with a prior allogeneic stem cell transplant
Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or who have taken calcineurin inhibitors within 4 weeks prior to consent; Substudies 3 and 4: all participants with a prior allogeneic stem cell transplant
Lab requirements
Kidney function
Substudies 1, 3, and 4: eGFR ≥ 50 mL/min; Substudy 2: eGFR ≥ 30 mL/min
Liver function
Adequate organ function
Adequate organ function; Substudies 1, 3, and 4: eGFR ≥ 50 mL/min; Substudy 2: eGFR ≥ 30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Phoenix · Phoenix, Arizona
- University of Southern California Norris Comprehensive · Los Angeles, California
- Mayo Clinic Jacksonville · Jacksonville, Florida
- Moffitt Cancer Center · Tampa, Florida
- The University of Kansas Cancer Center · Westwood, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06634589 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior none (treatment-naive B-cell malignancies), Bcl-2 inhibitor, CD20 x CD3 T-cell engager antibody disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages